CRMD Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.59%. CorMedix, Inc.'s return on equity of 95.25% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

CorMedix, Inc. has a consensus price target of $16.86, signalling upside risk potential of 148.63%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 30.11%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..

CorMedix, Inc. has a beta of 1.358, which suggesting that the stock is 35.753% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. CorMedix, Inc.'s net income of $108.6M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.30x while ANI Pharmaceuticals, Inc.'s PE ratio is 52.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.28x versus 2.07x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arcutis Biotherapeutics, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 7.47%. CorMedix, Inc.'s return on equity of 95.25% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

CorMedix, Inc. has a consensus price target of $16.86, signalling upside risk potential of 148.63%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 22.34%. Given that CorMedix, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

CorMedix, Inc. has a beta of 1.358, which suggesting that the stock is 35.753% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.710, suggesting its more volatile than the S&P 500 by 70.962%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. CorMedix, Inc.'s net income of $108.6M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.30x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.28x versus 10.38x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.24%. CorMedix, Inc.'s return on equity of 95.25% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

CorMedix, Inc. has a consensus price target of $16.86, signalling upside risk potential of 148.63%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.51%. Given that CorMedix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Amicus Therapeutics, Inc..

CorMedix, Inc. has a beta of 1.358, which suggesting that the stock is 35.753% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. CorMedix, Inc.'s net income of $108.6M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.30x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.28x versus 7.33x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 21.32%. CorMedix, Inc.'s return on equity of 95.25% beat Pfizer Inc.'s return on equity of 10.84%.

CorMedix, Inc. has a consensus price target of $16.86, signalling upside risk potential of 148.63%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that CorMedix, Inc. has higher upside potential than Pfizer Inc., analysts believe CorMedix, Inc. is more attractive than Pfizer Inc..

CorMedix, Inc. has a beta of 1.358, which suggesting that the stock is 35.753% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. CorMedix, Inc.'s net income of $108.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, CorMedix, Inc.'s price-to-earnings ratio is 3.30x while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 2.28x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.